(Q45200343)

10 December 2017

title

Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis (English)

1 reference

10 December 2017

T Korkmaz

1

1 reference

10 December 2017

S Seber

2

1 reference

10 December 2017

U Kefeli

3

1 reference

10 December 2017

E Sari

4

1 reference

10 December 2017

M Canhoroz

5

1 reference

10 December 2017

B Oven

6

1 reference

10 December 2017

E Yildirim

7

1 reference

10 December 2017

N Yasar

8

1 reference

10 December 2017

D Aydin

9

1 reference

10 December 2017

O Balvan

10

1 reference

10 December 2017

N Sener

11

1 reference

10 December 2017

S Yuksel

12

1 reference

10 December 2017

A Mert

13

1 reference

10 December 2017

O Polat

14

1 reference

10 December 2017

F Yumuk

15

1 reference

10 December 2017

O Kanat

16

1 reference

10 December 2017

M Gumus

17

1 reference

10 December 2017

N S Turhal

18

1 reference

10 December 2017

publication date

10 November 2012

1 reference

Clinical and Translational Oncology

10 December 2017

published in

1 reference

10 December 2017

volume

15

1 reference

10 December 2017

issue

7

1 reference

10 December 2017

page(s)

535-540

1 reference

10 December 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Small cell lung cancer: have we made any progress over the last 25 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Small cell lung cancer: current therapy and promising new regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

21 January 2018

Small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

Small Cell Lung Cancer: Patterns of care and their influence on survival - 25 years experience of a single Australian oncology unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0960-6

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group

1 reference

12 December 2020

Small cell lung cancer 1973–1983: Early progress and recent obstacles

1 reference

12 December 2020

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

12 December 2020

10.1007/S12094-012-0960-6

Identifiers

DOI

1 reference

Dimensions Publication ID

10 December 2017

1034863657

0 references

1 reference